Over the YEARS, the Medical Post has taken politicians to task for ineffective handling of health reform. To give them some credit, many political issues are complex with no clear-cut solution.
The state and its players find themselves at the heart of a battle between generic companies and innovator drug makers. And the two pharmaceutical lobbies are using numbers to duke it out.
Placebo response in clinical trials of antipsychotic medications is highly varied, which has implications for the design of placebo-controlled trials, according to a meta-analysis by Canadian investigators.
